<i>EGFR</i> Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?

The recent emergence of novel neoadjuvant and/or adjuvant therapies for early stage (I-IIIA) non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting <i>EGFR</i> mutations and immunotherapy or chemo-immunotherapy, has suddenly required the evaluation of b...

Full description

Bibliographic Details
Main Author: Paul Hofman
Format: Article
Published: MDPI AG 2021-08-01
Online Access:https://www.mdpi.com/2073-4409/10/8/2157